Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18210659 | 1.00 | PRMT6 (0.50) | PRMT6ALDH1A1HTR3EHTR3BHTR1D | |
| SCHEMBL12017183 | 0.98 | ALDH1A1 (0.49) | PRMT6ALDH1A1HTR3EHTR3BHTR1D | |
| SCHEMBL25450903 | 0.90 | PRMT6 (0.49) | PRMT6ALDH1A1HTR3EHTR3BHTR1D | |
| SCHEMBL4631841 | 0.84 | ALDH1A1 (0.50) | PRMT6ALDH1A1HTR3EHTR3BHTR1D | |
| SCHEMBL11947326 | 0.84 | ADRA2C (0.61) | ALDH1A1HTR3EHTR3BHTR1DHTR2C | |
| SCHEMBL3722272 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HTR3EHTR3BHTR1DHTR2C | |
| SCHEMBL270532 | 0.82 | HTR3E (0.71) | ALDH1A1HTR3EHTR3BHTR1DHTR2C | |
| SCHEMBL4402783 | 0.82 | LMNA (0.53) | ALDH1A1HTR3EHTR3BHTR1DHTR2C | |
| SCHEMBL14349176 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HTR3EHTR3BHTR1DHTR2C | |
| SCHEMBL117340 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HTR3EHTR3BHTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | Hepagene Therapeutics (HK) Limited (HK) | 2021-06-17 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9718821-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | PRMT6 111/4885ALDH1A1 4017/4885HTR3E 4106/4885 |
| US-20180072756-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TPMT, ADAR | PRMT6 581/4885ALDH1A1 2152/4885HTR3E 2947/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | PRMT6 2172/4885ALDH1A1 779/4885HTR3E 4003/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | PRMT6 1254/4885ALDH1A1 3235/4885HTR3E 1287/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | PRMT6 636/4885ALDH1A1 1825/4885HTR3E 4451/4885 |
| US-20230348435-A1 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | GPR139, GPR142, HTR2C | PRMT6 4031/4885ALDH1A1 975/4885HTR3E 52/4885 |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | IRAK1, IRAK2, IRAK3 | PRMT6 2233/4885ALDH1A1 1701/4885HTR3E 4584/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | PRMT6 2172/4885ALDH1A1 779/4885HTR3E 4003/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | PRMT6 1975/4885ALDH1A1 780/4885HTR3E 2906/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | PRMT6 484/4885ALDH1A1 2561/4885HTR3E 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.